Affymax (Affymax) Debt-to-Asset : 0.00 (As of Jun. 2014)

View and export this data going back to 2006. Start your Free Trial

What is Affymax Debt-to-Asset?

Affymax's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2014 was $0.00 Mil. Affymax's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2014 was $0.00 Mil. Affymax's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2014 was $5.38 Mil. Affymax's debt to asset for the quarter that ended in Jun. 2014 was 0.00.

Affymax Debt-to-Asset Historical Data

The historical data trend for Affymax's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax Debt-to-Asset Chart

Affymax Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.08

Affymax Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Affymax's Debt-to-Asset

For the Biotechnology subindustry, Affymax's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affymax's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affymax's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Affymax's Debt-to-Asset falls into.

Affymax Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Affymax's Debt-to-Asset for the fiscal year that ended in Dec. 2013 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	7.443
	=	0.00

Affymax's Debt-to-Asset for the quarter that ended in Jun. 2014 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	5.384
	=	0.00

Affymax (OTCPK:AFFY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Affymax Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Affymax's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax (Affymax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax Inc (OTCPK:AFFY) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Executives

John Peter Walker	director	126 ISABELLA AVE, ATHERTON CA 94027
John A Orwin	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Mark G Thompson	officer: Chief Financial Officer	8383 WILSHIRE BLVD BEVERLY HILLS CA 90211
Jeffrey H Knapp	officer: Chief Commercial Officer	4001 MIRANDA AVE. PALO ALTO CA 94304
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Anne-marie Duliege	officer: Chief Medical Officer	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Kathleen Laporte	director
Karin L Walker	officer: VP, Finance & CAO	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heek Christi Van	director	4001 MIRANDA AVENUE, PALO ALTO CA 94304
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Hollings Renton	director
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Paul B Cleveland	officer: EVP, Corp. Development and CFO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Arlene Morris	director, officer: CEO	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304

Affymax (Affymax) Headlines

From GuruFocus

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares

By GuruFocus Research GuruFocus Editor • 09-30-2009

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares

By GuruFocus Research GuruFocus Editor • 05-19-2010

AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares

By GuruFocus Research GuruFocus Editor • 02-26-2010

AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares

By GuruFocus Research GuruFocus Editor • 05-13-2010

AFFYMAX, INC. Reports Operating Results (10-Q)

By gurufocus • 08-05-2009

AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares

By gurufocus • 09-03-2009